[{"id":"ec6888d8-8567-44a4-9538-6cdb2ce914b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05055232","created_at":"2021-09-24T14:55:06.174Z","updated_at":"2025-02-25T17:12:00.677Z","phase":"Phase 1","brief_title":"A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05055232","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xuan Fei Ning (dirozalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 03/12/2023","primary_completion_date":" 03/12/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2021-09-24"}]